

PET Centre Western Private Hospital Ground Floor, 44 Eleanor Street Footscray, VIC 3013 P: +61 3 9304 7360 F: +91 3 9304 7361

E: petcentre@westernprivate.com.au

WESTPH\_PETIRO 06/25 ©2025. BARKER & BARKER MEDIA Pty Ltd

Referral forms may be downloaded from: www.westernprivatehospital.com.au/ clinical-services/pet-centre

Page 1 of 2

## PET/CT IMAGING REQUEST FORM ONCOLOGY / INFECTION / INFLAMMATION

	Please (	сотр	lete both sia	les & ensure for	rm is signe	ed by the refe	erring Consultant or MO o	n their behalf						
Date results required by:				or circle below	Patient Identification Details or Label (Three or more patient identifiers)									
< 3 days 1					nonths	WPH UR Number								
Reason for URGENT scan:							Surname							
Inpatient N Y Location						First Name								
Diabetes N Y Type						Date of Birth Sex at Birth: Male / Female								
Claustrophobic	N	Υ				Address								
Interpreter required	N	Υ	Language											
Radiotherapy Planning PET	N	Υ	Contact			Email:   Home/Work Phone:   Ho								
Clinical Trial	N	Υ	Trial Code			Mobile Phone: (Preferred)								
Clinic Trial Contact:							Alternate Contact Person - Phone:							
Tracer (please circle)				<sup>18</sup> F-FDG			<sup>18</sup> F-PSMA (prostate/RCC)	<sup>68</sup> Ga DOTATATE (neuroendocrine)						
PET/CT Clinical Indicat	ion							'						
Primary site of Disease:						Histology / Pathology:								
Key Clinical Question:														
Relevant History and Findings:														
Recent Biopsy / Surgery (please state)														
Recent / Ongoing Ty Chemotherapy Radiotherapy			Type	Cycle Length		Date	of Last Treatment	Date of Next Treatment						
Additional to the PET/C	CT. a full		O ::	O		RECENT CORRELATIVE IMAGING								
diagnostic CT is requested			Ves Yes	with IV o	contrast	СТ	Date	Where						
Exam region for Diagnostic CT						MRI	Date	Where						
eGFR:	Creat			Date		Other	Date	Where						
Referring Specialist Deta	ils *Me	edica	re requires	that to be reim	nbursable	, PET/CT sca	an must be specialist re	eferred						
Specialist Name					Email									
Provider Number					Address	SS								
Healthlink ID					Phone	Fax								
Your Name				Specialis	Specialist / M0 Signature Date									
Copies of report to					1									

Patien	t Name															
		Me	dicai	e Funded C	linica	I Ind	ications	Scan will	be bulk	k-b	illed if referred	d by a	Specialist			
[18F]	FDG PET	•														
	Evaluat	ion of a so	olitary p	oulmonary nodule	e (unsuit	able for	biopsy / failed pa	athologica	al chara	cte	erization) [6152	23]				
	Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if (a) the cancer is a typically FDG-avid cancer; and (b) there is at least 10% likelihood that PET study will inform a significant change in management for the patient [61612]  *Applicable once per cancer diagnosis*															
	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FDG-avid cancer [61614]															
[18F] PSMA PET																
	Whole body PSMA study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent [61563]  Intermediate to high-risk prostate adenocarcinoma, as defined by having at least one of the following risk factors;  PSA of 10-20 ng/mL, or Gleason score >7 / ISUP grade group 4 or 5, or Stage T2c or > T3  *Medicare will pay for a maximum of one service per lifetime*															
	Whole body PSMA study performed for the restaging of recurrent prostate adeocarcinoma, for a patient who has undergone locoregional therapy – either patients with a PSA increase of 2ng/mL above the nadir after radiation therapy; or failure of PSA levels to return to undetectable levels or rising PSA serum after a radical prostatectomy [61564]  *Medicare benefit payable for maximum of two services per lifetime*															
	Whole body PSMA study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with mCRPC, after progressive disease has developed while undergoing prior treatment with at least one of both -  Taxane chemotherapy (type/when):  Androgen receptor signalling inhibitor (type/when):  [61528]															
[68Ga	] DOTAT	ATE PET														
Whole body 68Ga DOTA peptide PET study, if a gastro entero pancreatic neuroendocrine tumour is suspected on basis of biochemical evidence with negative or equivocal conventional imaging OR both a surgically amenable GEP NET has been identified and the study is for excluding additional disease sites [61647]																
	Whole I	oody 68Ga	a DOTA	peptide PET stud	dy for pa	tients w	vith advanced or I	netastatio	c inoper	rab	le neuroendoc	rine n	eoplasms (f	rom 1 No	v 2025)	
[40F]	EDC DET		No	on MBS Clir	nical I	ndica	<b>itions</b> Plea	ase indica	ate who	is	meeting cost	of scal	7			
[18F]	FDG PET		) 2 0011	roo noomakar	nacomo	kor loo	do andocarditio	aroft / ata	nt							
	Inflamn		rmator	nyositis, Giant Ce			ds, endocarditis, disease, Large V			Poly	ymyalgia Rheu	ımatic	a, Retroperi	toneal Fib	rosis,	
			-	ast steroid thera	py and w	eaning	plan -									
[18F] PSMA PET																
Staging / Restaging of Clear Cell Renal Cell Cancer																
Other clinical indications -																
The co	ost of the	scan will	be me	t by												
l ——	Veteran's Affairs Patient Referring hospital (Dept)															
Trial S0					SOC	C ASOC Unit					Unit / Dept c	/ Dept contact				
EXAM CODE CHECKED BY NMP DATE																
SCAN	FROM Vertex Base of Brain			Т	TO Mid Thigh Dista			Thigh Knees Dist			Dista	al Primary	Arms	U D		
DDEDADATION			Busc	opan		Cardiac		Metformin Y / N				Stop date:				
PREPARATION		Neg (	Oral Contrast		NO Vis Stim			Propranolol				Saline +/- Lasix				